Gene expression analysis of membrane transporters and drug-metabolizing enzymes in the lung of healthy and COPD subjects

Pharmacology Research and Perspectives

Volumn 2, Issue 4, 2014, Pages

  Berg, Tove ^a   Hegelund Myrbäck, Tove ^b   Olsson, Marita ^b   Seidegård, Janeric ^b   Werkström, Viktoria ^b   Zhou, Xiao Hong ^b   Grunewald, Johan ^a   Gustavsson, Lena ^c   Nord, Magnus ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

central airways; ex smoker; expression pattern; human lung tissue; mRNA; PCA; PCR; peripheral tissue; pharmacokinetics; TLDA

Indexed keywords

ABC TRANSPORTER; ANTIBIOTIC AGENT; BENZODIAZEPINE; CARNITINE TRANSPORTER 1; CONCENTRATIVE NUCLEOSIDE TRANSPORTER 3; DRUG METABOLIZING ENZYME; FENTANYL; GLUCOSE TRANSPORTER 1; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; PROPOFOL;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG METABOLISM; DRUG UPTAKE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUNG; MALE; MRNA EXPRESSION ASSAY; PATIENT SAFETY; PHARMACOKINETICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION;

EID: 84986597590     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.54     Document Type: Article

References (33)

1. Aitken AE, Richardson TA, Morgan ET (2006). Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46: 123–149.
2. Bandi N, Kompella UB (2002). Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1). Eur J Pharmacol 437: 9–17.
3. Bauer M, Herbarth O, Aust G, Hengstler JG, Dotzauer A, Graebsch C, et al. (2006). Expression patterns and novel splicing variants of glutathione-S-transferase isoenzymes of human lung and hepatocyte cell lines. Cell Tissue Res 324: 423–432.
4. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, et al. (2006). Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36: 963–988.
5. Bosquillon C (2010). Drug transporters in the lung–do they play a role in the biopharmaceutics of inhaled drugs? J Pharm Sci 99: 2240–2255.
6. Budulac SE, Postma DS, Hiemstra PS, Lapperre TS, Kunz LI, Vonk JM, et al. (2012). Multidrug resistance-associated protein 1 and lung function decline with or without long-term corticosteroids treatment in COPD. Eur J Pharmacol 696: 136–142.
7. Byron PR (1986). Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 75: 433–438.
8. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650–1654.
9. Courcot E, Leclerc J, Lafitte JJ, Mensier E, Jaillard S, Gosset P, et al. (2012). Xenobiotic metabolism and disposition in human lung cell models: comparison with in vivo expression profiles. Drug Metab Dispos 40: 1953–1965.
10. Darquenne C (2012). Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv 25: 140–147.
11. van der Deen M, de Vries EG, Timens W, Scheper RJ, Timmer-Bosscha H, Postma DS (2005). ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res 6: 59.
12. van der Deen M, Timens W, Timmer-Bosscha H, van der Strate BW, Scheper RJ, Postma DS, et al. (2007). Reduced inflammatory response in cigarette smoke exposed Mrp1/Mdr1a/1b deficient mice. Respir Res 8: 49.
13. van der Deen M, Homan S, Timmer-Bosscha H, Scheper RJ, Timens W, Postma DS, et al. (2008). Effect of COPD treatments on MRP1-mediated transport in bronchial epithelial cells. Int J Chron Obstruct Pulmon Dis 3: 469–475.
14. Ding X, Kaminsky LS (2003). Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43: 149–173.
15. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discovery 9: 215–236.
16. Hallgren O, Nihlberg K, Dahlback M, Bjermer L, Eriksson LT, Erjefalt JS, et al. (2010). Altered fibroblast proteoglycan production in COPD. Respir Res 11: 55.
17. Hallgren O, Rolandsson S, Andersson-Sjoland A, Nihlberg K, Wieslander E, Kvist-Reimer M, et al. (2012). Enhanced ROCK1 dependent contractility in fibroblast from chronic obstructive pulmonary disease patients. J Transl Med 10: 171.
18. Harrison TW, Tattersfield AE (2003). Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 58: 258–260.
19. Horvath G, Schmid N, Fragoso MA, Schmid A, Conner GE, Salathe M, et al. (2007). Epithelial organic cation transporters ensure pH-dependent drug absorption in the airway. Am J Respir Cell Mol Biol 36: 53–60.
20. Hukkanen J, Pelkonen O, Hakkola J, Raunio H (2002). Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol 32: 391–411.
21. Kim JH, Sherman ME, Curriero FC, Guengerich FP, Strickland PT, Sutter TR (2004). Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol Appl Pharmacol 199: 210–219.
22. Leclerc J, Courcot-Ngoubo Ngangue E, Cauffiez C, Allorge D, Pottier N, Lafitte JJ, et al. (2011). Xenobiotic metabolism and disposition in human lung: transcript profiling in non-tumoral and tumoral tissues. Biochimie 93: 1012–1027.
23. Liu X, Jin L, Upham JW, Roberts MS (2013). The development of models for the evaluation of pulmonary drug disposition. Expert Opin Drug Metab Toxicol 9: 487–505.
24. Martin RJ (2002). Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 109: S447–S460.
25. Nakamura T, Nakanishi T, Haruta T, Shirasaka Y, Keogh JP, Tamai I (2010). Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm 7: 187–195.
26. Patton JS, Byron PR (2007). Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discovery 6: 67–74.
27. Pierrou S, Broberg P, O'Donnell RA, Pawlowski K, Virtala R, Lindqvist E, et al. (2007). Expression of genes involved in oxidative stress responses in airway epithelial cells of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 577–586.
28. Raunio H, Hakkola J, Hukkanen J, Lassila A, Paivarinta K, Pelkonen O, et al. (1999). Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Exp Toxicol Pathol 51: 412–417.
29. Seree E, Villard PH, Hever A, Guigal N, Puyoou F, Charvet B, et al. (1998). Modulation of MDR1 and CYP3A expression by dexamethasone: evidence for an inverse regulation in adrenals. Biochem Biophys Res Commun 252: 392–395.
30. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414–423.
31. Somers GI, Lindsay N, Lowdon BM, Jones AE, Freathy C, Ho S, et al. (2007). A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos 35: 1797–1805.
32. Storey JD, Tibshirani R (2003). Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100: 9440–9445.
33. Zhang JY, Wang Y, Prakash C (2006). Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab 7: 939–948.